Aktionsplan Soleno Therapeutics, Inc.
Erweiterter Zeitplan
Einfaches Diagramm
Über das Unternehmen
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
EBITDA |
-0.0159 |
Число акций ао |
0.01649 млрд |
P/BV |
6.24 |
EV/EBITDA |
-4.56 |
Цена ао |
54.92 |
ISIN |
US8342033094 |
Сайт |
https://soleno.life
|
Валюта |
usd |
IPO date |
2014-11-13 |
Sector |
Health Care |
Industry |
Biotechnology |
Валюта отчета |
usd |
Preisänderung pro Tag: |
-1.12% (55.54) |
Preisänderung pro Woche: |
+12.2% (48.95) |
Preisänderung pro Monat: |
+13.05% (48.58) |
Preisänderung über 3 Monate: |
+15.21% (47.67) |
Preisänderung über sechs Monate: |
+42.58% (38.52) |
Preisänderung pro Jahr: |
+124.44% (24.47) |
Preisänderung über 3 Jahre: |
+5 840.51% (0.9245) |
Preisänderung über 5 Jahre: |
+2 868.65% (1.85) |
Preisänderung seit Jahresbeginn: |
+146.22% (22.305) |
|
Unterschätzung
Name |
Bedeutung |
Grad |
P/S |
0 |
0 |
P/BV |
3.97 |
4 |
P/E |
0 |
0 |
EV/EBITDA |
-12.41 |
0 |
Gesamt: |
|
2.25 |
|
Effizienz
Name |
Bedeutung |
Grad |
ROA, % |
-21.58 |
0 |
ROE, % |
-24.75 |
0 |
Gesamt: |
|
0 |
|
|
Dividenden
Name |
Bedeutung |
Grad |
Div yield, % |
0 |
0 |
DSI |
0 |
0 |
Gesamt: |
|
0 |
|
Pflicht
Name |
Bedeutung |
Grad |
Debt/EBITDA |
-0.011 |
10 |
Gesamt: |
|
8.2 |
|
Wachstumsimpuls
Name |
Bedeutung |
Grad |
Rentabilität Revenue, % |
-51866.73 |
0 |
Rentabilität Ebitda, % |
130.89 |
10 |
Rentabilität EPS, % |
-85.02 |
0 |
Gesamt: |
|
3.6 |
|
Aufsicht |
Berufsbezeichnung |
Zahlung |
Geburtsjahr |
Dr. Anish Bhatnagar M.D. |
President, CEO, COO & Director |
1.06M |
1970 (54 Jahr) |
Mr. James H. MacKaness |
Chief Financial Officer |
640k |
1964 (60 Jahre) |
Dr. Neil M. Cowen M.B.A., Ph.D. |
Senior Vice President of Drug Development |
N/A |
|
Ms. Kristen Yen M.S. |
Senior Vice President of Clinical Operations |
317.19k |
1969 (55 Jahre) |
Ms. Meredith Manning M.B.A. |
Chief Commercial Officer |
N/A |
1972 (52 Jahr) |
Ms. Patricia C. Hirano M.P.H. |
Senior Vice President of Regulatory Affairs |
493k |
1966 (58 Jahre) |
Ms. Lauren Budesheim |
Vice President of People |
N/A |
|
Dr. Michael Huang M.D. |
Senior Vice President of Clinical Development |
N/A |
1974 (50 Jahre) |
Dr. Raymond W. Urbanski M.D., Ph.D. |
Chief Development Officer |
|
1959 (65 Jahre) |